CAR-T therapy for advanced head and neck cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your head and neck cancer must be advanced and no longer responding to standard treatments.
- Your tumor must have high levels of a protein called Trop2 (score 2+ and at least 40% of cells).
- You must be able to walk and take care of yourself (ECOG score 0 or 1).
- You cannot have had certain previous treatments like CAR-T therapy or cancer vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests an investigational cell therapy called Trop2 CAR-NK for people with advanced non-small cell lung cancer that has come back after standard treatments. The therapy uses your own immune cells (natural killer cells) that are specially trained to find and attack cancer cells that carry the Trop2 protein. This may help shrink tumors or slow the cancer's growth.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Nasopharynx Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.